OPKO Health, Inc. (NASDAQ:OPK) CEO Buys $198,750.00 in Stock

OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) CEO Phillip Md Et Al Frost purchased 125,000 shares of OPKO Health stock in a transaction on Friday, December 13th. The shares were acquired at an average price of $1.59 per share, for a total transaction of $198,750.00. Following the completion of the transaction, the chief executive officer now directly owns 212,536,477 shares of the company's stock, valued at approximately $337,932,998.43. The trade was a 0.06 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Wednesday, December 11th, Phillip Md Et Al Frost acquired 500,000 shares of OPKO Health stock. The stock was bought at an average price of $1.56 per share, for a total transaction of $780,000.00.
• On Friday, November 29th, Phillip Md Et Al Frost purchased 199,072 shares of OPKO Health stock. The stock was bought at an average cost of $1.53 per share, for a total transaction of $304,580.16.
• On Friday, November 22nd, Phillip Md Et Al Frost purchased 100,000 shares of OPKO Health stock. The shares were purchased at an average price of $1.59 per share, with a total value of $159,000.00.
• On Thursday, November 14th, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The shares were purchased at an average price of $1.62 per share, with a total value of $162,000.00.
• On Friday, November 8th, Phillip Md Et Al Frost bought 280,183 shares of OPKO Health stock. The shares were acquired at an average cost of $1.50 per share, for a total transaction of $420,274.50.

OPKO Health Stock Performance

Shares of NASDAQ OPK traded down $0.02 during midday trading on Friday, hitting $1.59. 3,044,472 shares of the company's stock traded hands, compared to its average volume of 6,804,103. The firm has a fifty day moving average of $1.53 and a 200 day moving average of $1.47. OPKO Health, Inc. has a 1 year low of $0.85 and a 1 year high of $1.76. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. CIBC Asset Management Inc grew its position in shares of OPKO Health by 79.1% during the 2nd quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company's stock valued at $25,000 after acquiring an additional 8,978 shares during the period. FMR LLC lifted its position in OPKO Health by 103.6% during the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company's stock valued at $32,000 after purchasing an additional 11,089 shares in the last quarter. Algert Global LLC bought a new stake in OPKO Health during the second quarter valued at about $44,000. Orion Portfolio Solutions LLC purchased a new stake in OPKO Health in the third quarter worth about $45,000. Finally, Private Advisor Group LLC raised its stake in shares of OPKO Health by 242.7% in the third quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company's stock worth $53,000 after buying an additional 25,000 shares during the period. 64.63% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on OPK. HC Wainwright reissued a "buy" rating and issued a $3.00 price target on shares of OPKO Health in a research note on Thursday, September 26th. Barrington Research reissued an "outperform" rating and issued a $2.25 target price on shares of OPKO Health in a research report on Friday, November 8th. Finally, Piper Sandler restated an "overweight" rating and set a $3.00 price target on shares of OPKO Health in a research report on Tuesday, September 17th.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.